{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:36:37Z","timestamp":1767141397250,"version":"build-2238731810"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In patients with advanced non-small cell lung cancer (NSCLC),\n                    <jats:italic>MET<\/jats:italic>\n                    exon 14 (\n                    <jats:italic>MET<\/jats:italic>\n                    ex14) skipping mutations are rare and are associated with a poor prognosis. Capmatinib, a selective oral MET inhibitor, was recently approved for the treatment of advanced\n                    <jats:italic>MET<\/jats:italic>\n                    ex14 skipping NSCLC. However, data from real-world experiences are limited. This was a retrospective analysis using real-world data from Italian patients with advanced\n                    <jats:italic>MET<\/jats:italic>\n                    ex14 skipping NSCLC who had received at least one treatment with immunotherapy and\/or platinum-based chemotherapy and received compassionate use treatment with capmatinib. Patient characteristics, treatment details, discontinuations, and adverse events are reported. Overall, 53 patients received capmatinib after receiving treatment with immunotherapy and\/or platinum-based chemotherapy in Italy. Patients had a median age of 74\u00a0years, mostly metastatic disease (92.5% of patients), and previously received one (66.0%) or more (2: 28.3%; 3: 5.7%) lines of standard treatment (immunotherapy and\/or platinum-based chemotherapy). Most patients (98.1%) started treatment with capmatinib at the full recommended dose of 400\u00a0mg twice daily and 77.4% did not require a dose reduction. Twenty-four patients (45.3%) discontinued treatment; the most frequent reason for discontinuing treatment was disease progression, with a median estimated time to treatment discontinuation of 15.2\u00a0months. This real-world retrospective analysis confirms that capmatinib is a valuable treatment option for difficult-to-treat\n                    <jats:italic>MET<\/jats:italic>\n                    ex14 skipping NSCLC, in agreement with the data from the registration trial.\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01934-2","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:29:55Z","timestamp":1763432995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy"],"prefix":"10.1007","volume":"26","author":[{"given":"Fabiana Letizia","family":"Cecere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-9876","authenticated-orcid":false,"given":"Ettore","family":"D\u2019Argento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-1728","authenticated-orcid":false,"given":"Francesco","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7735-8973","authenticated-orcid":false,"given":"Francesco","family":"Pesola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-5076","authenticated-orcid":false,"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6922-1934","authenticated-orcid":false,"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-4970","authenticated-orcid":false,"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3742-9962","authenticated-orcid":false,"given":"Gianluca","family":"Spitaleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3268-0876","authenticated-orcid":false,"given":"Diletta","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1363-899X","authenticated-orcid":false,"given":"Ilaria","family":"Marcon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-7369","authenticated-orcid":false,"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1934_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009.","journal-title":"Ann Oncol"},{"key":"1934_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1934_CR3","unstructured":"Associazione Italiana di Oncologia Medica (AIOM). I numeri del cancro il Italia 2023 [in Italian]. 2023. https:\/\/www.aiom.it\/wp-content\/uploads\/2023\/12\/2023_AIOM_NDC-web.pdf. Accessed 13 Nov 2024."},{"key":"1934_CR4","unstructured":"World Health Organization. Lung cancer: fact sheet. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer. Accessed 17 Dec 2024."},{"key":"1934_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group. Ann Oncol. 2024;35:588\u2013606. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005.","journal-title":"Ann Oncol"},{"key":"1934_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1126\/science.1846706","volume":"251","author":"DP Bottaro","year":"1991","unstructured":"Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802\u20134. https:\/\/doi.org\/10.1126\/science.1846706.","journal-title":"Science"},{"key":"1934_CR7","unstructured":"National Center for Biotechnology Information. MET. MET proto-oncogene, receptor tyrosine kinase [Homo sapiens (human)]. 2025. https:\/\/www.ncbi.nlm.nih.gov\/gene\/4233\/#summary. Accessed 29 Jul 2025."},{"key":"1934_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.6004\/jadpro.2022.13.5.8","volume":"13","author":"A Desai","year":"2022","unstructured":"Desai A, Cuellar S. The current landscape for METex14 skipping mutations in non-small cell lung cancer. J Adv Pract Oncol. 2022;13:539\u201344. https:\/\/doi.org\/10.6004\/jadpro.2022.13.5.8.","journal-title":"J Adv Pract Oncol"},{"key":"1934_CR9","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.jtocrr.2023.100630","volume":"5","author":"Y Han","year":"2024","unstructured":"Han Y, Yu Y, Miao D, et al. Targeting MET in NSCLC: an ever-expanding territory. JTO Clin Res Rep. 2024;5:100630. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100630.","journal-title":"JTO Clin Res Rep"},{"key":"1934_CR10","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.3390\/cancers15143561","volume":"15","author":"R Hsu","year":"2023","unstructured":"Hsu R, Benjamin DJ, Nagasaka M. The development and role of capmatinib in the treatment of MET-dysregulated non-small cell lung cancer-a narrative review. Cancers (Basel). 2023;15:3561. https:\/\/doi.org\/10.3390\/cancers15143561.","journal-title":"Cancers (Basel)"},{"key":"1934_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","volume":"34","author":"MM Awad","year":"2016","unstructured":"Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34:721\u201330. https:\/\/doi.org\/10.1200\/JCO.2015.63.4600.","journal-title":"J Clin Oncol"},{"key":"1934_CR12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","volume":"11","author":"AB Schrock","year":"2016","unstructured":"Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11:1493\u2013502. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.004.","journal-title":"J Thorac Oncol"},{"key":"1934_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383:944\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2002787.","journal-title":"N Engl J Med"},{"key":"1934_CR14","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","volume":"29","author":"JK Sabari","year":"2018","unstructured":"Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29:2085\u201391. https:\/\/doi.org\/10.1093\/annonc\/mdy334.","journal-title":"Ann Oncol"},{"key":"1934_CR15","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","volume":"22","author":"JH Tong","year":"2016","unstructured":"Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22:3048\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2061.","journal-title":"Clin Cancer Res"},{"key":"1934_CR16","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1097\/JTO.0000000000000620","volume":"10","author":"SF Yeung","year":"2015","unstructured":"Yeung SF, Tong JHM, Law PPW, et al. Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor. J Thorac Oncol. 2015;10:1292\u2013300. https:\/\/doi.org\/10.1097\/JTO.0000000000000620.","journal-title":"J Thorac Oncol"},{"key":"1934_CR17","unstructured":"European Medicines Agency. Tabrecta (capmatinib): summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tabrecta-epar-product-information_en.pdf. Accessed 13 Nov 2024."},{"key":"1934_CR18","unstructured":"European Medicines Agency. TEMPMETKO (tepotinib): summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tepmetko-epar-product-information_en.pdf. Accessed 13 Nov 2024."},{"key":"1934_CR19","unstructured":"US Food and Drug Administration. TABRECTA\u00ae (capmatinib) tablets, for oral use: prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213591s011lbl.pdf. Accessed 13 Nov 2024."},{"key":"1934_CR20","unstructured":"US Food and Drug Administration. TEPMETKO\u00ae (tepotinib) tablets, for oral use: prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214096s003lbl.pdf. Accessed 13 Nov 2024."},{"key":"1934_CR21","doi-asserted-by":"publisher","first-page":"102173","DOI":"10.1016\/j.ctrv.2021.102173","volume":"95","author":"YL Wu","year":"2021","unstructured":"Wu YL, Smit EF, Bauer TM. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: a review of preclinical and clinical studies. Cancer Treat Rev. 2021;95:102173. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102173.","journal-title":"Cancer Treat Rev"},{"key":"1934_CR22","unstructured":"Agenzia Italiano del Farmaco (AIFA). Tabrecta (capmatinib): valutazione dell\u2019innovativita\u2013Versione 1.0 [in Italian]. 2023. https:\/\/www.aifa.gov.it\/documents\/20142\/1874027\/62_TABRECTA_scheda+innovativita_GRADE.pdf. Accessed 13 Nov 2024."},{"key":"1934_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","volume":"25","author":"J Wolf","year":"2024","unstructured":"Wolf J, Hochmair M, Han JY, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024;25:1357\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(24)00441-8.","journal-title":"Lancet Oncol"},{"key":"1934_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2022.10.030","volume":"183","author":"J Wolf","year":"2023","unstructured":"Wolf J, Garon EB, Groen HJM, et al. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023;183:98\u2013108. https:\/\/doi.org\/10.1016\/j.ejca.2022.10.030.","journal-title":"Eur J Cancer"},{"key":"1934_CR25","doi-asserted-by":"publisher","first-page":"175883592211032","DOI":"10.1177\/17588359221103206","volume":"14","author":"O Illini","year":"2022","unstructured":"Illini O, Fabikan H, Swalduz A, et al. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol. 2022;14:17588359221103206. https:\/\/doi.org\/10.1177\/17588359221103206.","journal-title":"Ther Adv Med Oncol"},{"key":"1934_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2217\/fon-2022-1133","volume":"19","author":"PK Paik","year":"2023","unstructured":"Paik PK, Goyal RK, Cai B, et al. Real-world outcomes in non-small-cell lung cancer patients with MET exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023;19:217\u201328. https:\/\/doi.org\/10.2217\/fon-2022-1133.","journal-title":"Future Oncol"},{"key":"1934_CR27","doi-asserted-by":"publisher","first-page":"107934","DOI":"10.1016\/j.lungcan.2024.107934","volume":"196","author":"M Ferreira","year":"2024","unstructured":"Ferreira M, Swalduz A, Greillier L, et al. Capmatinib efficacy for METex14 non-small cell lung cancer patients: results of the IFCT-2104 CAPMATU study. Lung Cancer. 2024;196:107934. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107934.","journal-title":"Lung Cancer"},{"key":"1934_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw262","volume":"109","author":"AB Cortot","year":"2017","unstructured":"Cortot AB, Kherrouche Z, Descarpentries C, et al. Exon 14 deleted MET receptor as a new biomarker and target in cancers. J Natl Cancer Inst. 2017;109:djw262. https:\/\/doi.org\/10.1093\/jnci\/djw262.","journal-title":"J Natl Cancer Inst"},{"key":"1934_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","volume":"5","author":"GM Frampton","year":"2015","unstructured":"Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0285.","journal-title":"Cancer Discov"},{"key":"1934_CR30","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.esmoop.2024.103680","volume":"9","author":"ML Reale","year":"2024","unstructured":"Reale ML, Passiglia F, Cappuzzo F, et al. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database. ESMO Open. 2024;9:103680. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103680.","journal-title":"ESMO Open"},{"key":"1934_CR31","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.3390\/cancers15112932","volume":"15","author":"C Heydt","year":"2023","unstructured":"Heydt C, Ihle MA, Merkelbach-Bruse S. Overview of molecular detection technologies for MET in lung cancer. Cancers (Basel). 2023;15:2932. https:\/\/doi.org\/10.3390\/cancers15112932.","journal-title":"Cancers (Basel)"},{"key":"1934_CR32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2217\/fon-2023-1064","volume":"20","author":"M Furqan","year":"2024","unstructured":"Furqan M, Karanth S, Goyal RK, et al. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024;20:1553\u201363. https:\/\/doi.org\/10.2217\/fon-2023-1064.","journal-title":"Future Oncol"},{"key":"1934_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cllc.2023.06.008","volume":"24","author":"J Mazieres","year":"2023","unstructured":"Mazieres J, Vioix H, Pfeiffer BM, et al. MET exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes. Clin Lung Cancer. 2023;24:483\u201397. https:\/\/doi.org\/10.1016\/j.cllc.2023.06.008.","journal-title":"Clin Lung Cancer"},{"key":"1934_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11523-023-00976-4","volume":"18","author":"H Babey","year":"2023","unstructured":"Babey H, Jamme P, Curcio H, et al. Real-world treatment outcomes of MET exon14 skipping in non-small cell lung cancer: gfpc 03\u201318 study. Target Oncol. 2023;18:585\u201391. https:\/\/doi.org\/10.1007\/s11523-023-00976-4.","journal-title":"Target Oncol"},{"key":"1934_CR35","doi-asserted-by":"publisher","first-page":"114158","DOI":"10.1016\/j.ejca.2024.114158","volume":"207","author":"A Kron","year":"2024","unstructured":"Kron A, Scheffler M, Wiesweg M, et al. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations. Eur J Cancer. 2024;207:114158. https:\/\/doi.org\/10.1016\/j.ejca.2024.114158.","journal-title":"Eur J Cancer"},{"key":"1934_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115085","author":"C Sini","year":"2024","unstructured":"Sini C, Di Federico A, Bironzo P, De Giglio A, Gelsomino F. Letter re: indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations. Eur J Cancer. 2024. https:\/\/doi.org\/10.1016\/j.ejca.2024.115085.","journal-title":"Eur J Cancer"},{"key":"1934_CR37","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/CMAR.S386799","volume":"15","author":"M Fraser","year":"2023","unstructured":"Fraser M, Seetharamu N, Diamond M, Lee CS. Profile of capmatinib for the treatment of metastatic non-small cell lung cancer (NSCLC): patient selection and perspectives. Cancer Manag Res. 2023;15:1233\u201343. https:\/\/doi.org\/10.2147\/CMAR.S386799.","journal-title":"Cancer Manag Res"},{"key":"1934_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10637-024-01437-z","volume":"42","author":"W Li","year":"2024","unstructured":"Li W, Wang W. Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance. Invest New Drugs. 2024;42:335\u20139. https:\/\/doi.org\/10.1007\/s10637-024-01437-z.","journal-title":"Invest New Drugs"},{"key":"1934_CR39","doi-asserted-by":"publisher","first-page":"11388","DOI":"10.1038\/s41598-024-62356-w","volume":"14","author":"Y Qi","year":"2024","unstructured":"Qi Y, Li J, Lin S, et al. A real-world pharmacovigilance study of FDA adverse event reporting system events for capmatinib. Sci Rep. 2024;14:11388. https:\/\/doi.org\/10.1038\/s41598-024-62356-w.","journal-title":"Sci Rep"}],"updated-by":[{"DOI":"10.1007\/s10238-025-01988-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000}}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01934-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T03:33:52Z","timestamp":1766028832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01934-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1934"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01934-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10238-025-01988-2","URL":"https:\/\/doi.org\/10.1007\/s10238-025-01988-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fabiana Cecere declares no conflicts of interest. Ettore D\u2019Argento declares no conflicts of interest. Francesco Gelsomino has received honoraria for advisory roles or consulting from Eli Lilly, Novartis, AstraZeneca, Regeneron, Pfizer, and BMS outside of this work. Francesco Pesola has received honoraria for advisory roles or consulting from Novartis and Italfarmaco. Paolo Bironzo has received honoraria for advisory roles or consulting from AstraZeneca, Diaceutics, Johnson and Johnson, Pierre-Fabre, Regeneron, and Seagen outside of this work. He received institutional research grants from Pfizer and Roche. Salvatore Grisanti received fees for advisory boards from the following companies: AstraZeneca, BMS, MSD, Novartis, Pfizer, Regeneron, Roche, and Takeda. Laura Bonanno received speaker fees or honoraria for advisory boards from AstraZeneca, MSD, BMS, Roche, Pfizer, Novartis, Takeda, and Lilly; research support from AstraZeneca; served as coordinating PI and participated in a steering committee for AstraZeneca. Gianluca Spitaleri received honoraria for advisory boards from Takeda. Diletta Valsecchi is an employee at Novartis Farma spa. Ilaria Marcon is an employee at Novartis Farma spa. Diego Cortinovis has acted as a consultant or advisor to Roche, AstraZeneca, BMS, MSD, Boehringer Ingelheim, Amgen, Novartis, Lilly, Seagen, Takeda, GSK, BeiGene, Pfizer, and J&J\/Thermo Fisher Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The treating physicians obtained written informed consent, related to the treatment in compassionate use and the processing and use of data, from all participants or their representatives prior to the start of treatment, in accordance with local laws and regulations and in line with the ethical principles outlined in the Declaration of Helsinki. As per the local laws and regulations (DECREE 17A07305 [\n                      GU Serie Generale n.256 del 02\u201311-2017\n                      ]), ethics approval was not required for this retrospective analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"18"}}